PMID- 37537027
OWN - NLM
STAT- Publisher
LR  - 20230814
IS  - 1769-6658 (Electronic)
IS  - 1278-3218 (Linking)
VI  - 27
IP  - 5
DP  - 2023 Sep
TI  - [Stereotactic Body Radiation Therapy for less than 3cm (stage I) and 5cm (stage 
      II) inoperable lung tumors: 10 years experience of Montpellier Cancer Institute].
PG  - 387-397
LID - S1278-3218(23)00118-X [pii]
LID - 10.1016/j.canrad.2023.05.002 [doi]
AB  - PURPOSE: Search for predictive factors on survival and local control for less 
      than 3 centimeters (cm) (stage I) and 5cm (stage II) inoperable lung tumors 
      treated by Stereotactic Body Radiation Therapy (SBRT) in a retrospective 
      monocentric study from Montpellier Cancer Institute (ICM) PATIENTS AND METHOD: 
      Every patients treated at ICM for a stage I or II inoperable lung tumors from 
      2009 to 2019 were analyzed. RESULTS: One hundred and seventy nine lesions were 
      treated in 176 patients, with a major part (82,7%) in operated due to chronic 
      obstructive pulmonary disease. Median overall survival for all patients was 71,7 
      months with a 35 months follow-up and the 2 years loco-regional free survival was 
      94,0 months. Better associated outcomes were stage I (median overall survival 
      71,7 versus 29,0 months P=0,004 ; HR=2,37 P=0,005), BED>/=150Gy (median 
      time-to-progression not reached versus 76,7 months P=0,025), small size of 
      Planning Target Volume (PTV) (HR=0,42 P=0,032 when PTV<15,6 cc). 7,3% of all 
      patients developed radiation pneumonitis. CONCLUSION: SBRT is associated with an 
      excellent overall survival and a high rate of local control for less than 3cm 
      (stage I) and 5cm (stage II) lung tumors but a low rate of toxicities. For these 
      patients with many comorbidities, BED over 150Gy seems to be associated with a 
      better loco-regional free survival, while cause of death is often other than lung 
      cancer.
CI  - Copyright (c) 2023 Societe francaise de radiotherapie oncologique (SFRO). Published 
      by Elsevier Masson SAS. All rights reserved.
FAU - Marguerit, A
AU  - Marguerit A
AD  - Service d'oncologie-radiotherapie, institut du cancer de Montpellier, 208, avenue 
      des Apothicaires, 34090 Montpellier, France. Electronic address: 
      alexis.marguerit@icm.unicancer.fr.
FAU - Azria, D
AU  - Azria D
AD  - Service d'oncologie-radiotherapie, institut du cancer de Montpellier, 208, avenue 
      des Apothicaires, 34090 Montpellier, France.
FAU - Riou, O
AU  - Riou O
AD  - Service d'oncologie-radiotherapie, institut du cancer de Montpellier, 208, avenue 
      des Apothicaires, 34090 Montpellier, France.
FAU - Demontoy, S
AU  - Demontoy S
AD  - Service d'oncologie-radiotherapie, institut du cancer de Montpellier, 208, avenue 
      des Apothicaires, 34090 Montpellier, France.
FAU - Thezenas, S
AU  - Thezenas S
AD  - Service de statistiques, institut du cancer de Montpellier, 208, avenue des 
      Apothicaires, 34090 Montpellier, France.
FAU - Boisselier, P
AU  - Boisselier P
AD  - Service d'oncologie-radiotherapie, institut du cancer de Montpellier, 208, avenue 
      des Apothicaires, 34090 Montpellier, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Radiotherapie stereotaxique (RTST) pulmonaire des tumeurs de moins de 3cm (stade 
      I) et 5cm (stade II) non operees : 10 ans d'experience de l'Institut du Cancer de 
      Montpellier (ICM).
DEP - 20230801
PL  - France
TA  - Cancer Radiother
JT  - Cancer radiotherapie : journal de la Societe francaise de radiotherapie 
      oncologique
JID - 9711272
SB  - IM
OTO - NOTNLM
OT  - Cancer bronchique
OT  - Lung cance
OT  - Montpellier
OT  - Radiotherapie stereotaxique
OT  - SBRT
OT  - Stereotactic Body Radiation
EDAT- 2023/08/04 01:07
MHDA- 2023/08/04 01:07
CRDT- 2023/08/03 21:54
PHST- 2022/11/08 00:00 [received]
PHST- 2023/04/30 00:00 [revised]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/08/04 01:07 [pubmed]
PHST- 2023/08/04 01:07 [medline]
PHST- 2023/08/03 21:54 [entrez]
AID - S1278-3218(23)00118-X [pii]
AID - 10.1016/j.canrad.2023.05.002 [doi]
PST - ppublish
SO  - Cancer Radiother. 2023 Sep;27(5):387-397. doi: 10.1016/j.canrad.2023.05.002. Epub 
      2023 Aug 1.